628 related articles for article (PubMed ID: 15879619)
21. Current treatments of primary sclerosing cholangitis.
Vacca M; Krawczyk M; Petruzzelli M; Sasso RC; van Erpecum KJ; Palasciano G; van Berge-Henegouwen GP; Moschetta A; Portincasa P
Curr Med Chem; 2007; 14(19):2081-94. PubMed ID: 17691949
[TBL] [Abstract][Full Text] [Related]
22. [Treatment of cholestatic liver disease].
Pleşa A
Rev Med Chir Soc Med Nat Iasi; 2003; 107(4):733-6. PubMed ID: 14756010
[TBL] [Abstract][Full Text] [Related]
23. Liver transplantation for primary biliary cirrhosis and primary sclerosing cholangitis: does medical treatment alter timing and selection?
Hay JE
Liver Transpl Surg; 1998 Sep; 4(5 Suppl 1):S9-17. PubMed ID: 9742489
[TBL] [Abstract][Full Text] [Related]
24. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy.
Chazouillères O; Wendum D; Serfaty L; Montembault S; Rosmorduc O; Poupon R
Hepatology; 1998 Aug; 28(2):296-301. PubMed ID: 9695990
[TBL] [Abstract][Full Text] [Related]
25. [Autoimmune mediated cholestatic liver diseases].
Mayer LS; Käser R; Böttler T
Dtsch Med Wochenschr; 2020 Mar; 145(5):296-305. PubMed ID: 32120404
[TBL] [Abstract][Full Text] [Related]
26. Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid.
Jazrawi RP; de Caestecker JS; Goggin PM; Britten AJ; Joseph AE; Maxwell JD; Northfield TC
Gastroenterology; 1994 Jan; 106(1):134-42. PubMed ID: 8276175
[TBL] [Abstract][Full Text] [Related]
27. Primary sclerosing cholangitis.
Stiehl A; Benz C; Sauer P
Can J Gastroenterol; 2000 Apr; 14(4):311-5. PubMed ID: 10799084
[TBL] [Abstract][Full Text] [Related]
28. Treatment of chronic active hepatitis and primary biliary cirrhosis with ursodeoxycholic acid.
Güldütuna S; Leuschner U; Imhof M; Zimmer G
Z Gastroenterol; 1992 Mar; 30 Suppl 1():49-54. PubMed ID: 1449017
[TBL] [Abstract][Full Text] [Related]
29. Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode.
Kotb MA
Int J Mol Sci; 2012; 13(7):8882-8914. PubMed ID: 22942741
[TBL] [Abstract][Full Text] [Related]
30. Treatment of primary biliary cirrhosis: therapy with choleretic and immunosuppressive agents.
Silveira MG; Lindor KD
Clin Liver Dis; 2008 May; 12(2):425-43; x-xi. PubMed ID: 18456189
[TBL] [Abstract][Full Text] [Related]
31. [Treatment of cholestatic liver diseases].
Karvonen AL
Duodecim; 2003; 119(6):533-9. PubMed ID: 12708340
[No Abstract] [Full Text] [Related]
32. Diagnosis and management of overlap syndromes.
Bunchorntavakul C; Reddy KR
Clin Liver Dis; 2015 Feb; 19(1):81-97. PubMed ID: 25454298
[TBL] [Abstract][Full Text] [Related]
33. Cytoprotection with ursodeoxycholic acid: effect in chronic non-cholestatic and chronic cholestatic liver disease.
Lirussi F; Okolicsanyi L
Ital J Gastroenterol; 1992 Jan; 24(1):31-5. PubMed ID: 1571577
[TBL] [Abstract][Full Text] [Related]
34. The management of primary sclerosing cholangitis.
Mitchell SA; Chapman RW
Clin Liver Dis; 1998 May; 2(2):353-72, x. PubMed ID: 15560037
[TBL] [Abstract][Full Text] [Related]
35. Fibrates and cholestasis.
Ghonem NS; Assis DN; Boyer JL
Hepatology; 2015 Aug; 62(2):635-43. PubMed ID: 25678132
[TBL] [Abstract][Full Text] [Related]
36. Overlap syndromes of cholestatic liver diseases and auto-immune hepatitis.
Schramm C; Lohse AW
Clin Rev Allergy Immunol; 2005 Apr; 28(2):105-14. PubMed ID: 15879617
[TBL] [Abstract][Full Text] [Related]
37. [Possible treatment modalities of primary sclerosing cholangitis].
Lengyel G; Tulassay Z
Orv Hetil; 2005 Dec; 146(49):2479-83. PubMed ID: 16398312
[TBL] [Abstract][Full Text] [Related]
38. [Immune-mediated cholangiopathies : Diagnostic and therapeutic challenges].
Herta T; Beuers U
Radiologe; 2019 Apr; 59(4):348-356. PubMed ID: 30874827
[TBL] [Abstract][Full Text] [Related]
39. Transplantation trends in primary biliary cirrhosis.
Lee J; Belanger A; Doucette JT; Stanca C; Friedman S; Bach N
Clin Gastroenterol Hepatol; 2007 Nov; 5(11):1313-5. PubMed ID: 17900996
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic role of bile acids and nuclear receptor agonists in fibrosing cholangiopathies.
Trauner M; Halilbasic E; Kazemi-Shirazi L; Kienbacher C; Staufer K; Traussnigg S; Hofer H
Dig Dis; 2014; 32(5):631-6. PubMed ID: 25034298
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
